Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
VRTX - Vertex Pharmaceuticals Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$552.80
DETAILS
HIGH:
$616.00
LOW:
$436.00
MEDIAN:
$558.00
CONSENSUS:
$552.80
UPSIDE:
27.22%
Stock News
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t.
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
Breakfast News: PINS Mood Board Is Turning Bullish
Pinterest delivers strong results, Apple looks for new chip manufacturers, and more
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript
Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.23 per share. This compares to earnings of $4.06 per share a year ago.
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
Vertex Reports First Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “CASGEVY and J.
Breakfast News: Abel Takes Berkshire Center Stage
Berkshire Hathaway shareholders meet, GameStop launches bid for eBay, and more
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next
Alphabet's various businesses generate reliable revenue regardless of the economic backdrop. American Express' affluent cardholder base appears able to keep spending even as many consumers can't right now.
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering
These companies are leaders in their fields.
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Price Targets
Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays
$615.00
(was $424.36)
Barclays
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
$616.00
(was $417.72)
Morgan Stanley
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
$543.00
(was $429.85)
Brian Abrahams
·
RBC Capital
Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
$572.00
(was $429.85)
Bernstein
Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
$436.00
(was $429.85)
Canaccord Genuity
Vertex Pharmaceuticals price target lowered to $437 from $441 at Canaccord
$437.00
(was $423.24)
Canaccord Genuity
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley
$612.00
(was $436.89)
Morgan Stanley
Vertex (VRTX) PT Raised to $525 at Truist Securities
$525.00
(was $499.14)
Joon Lee
·
Truist Financial
Jefferies Starts Vertex (VRTX) at Buy
$580.00
(was $496.50)
Akash Tewari
·
Jefferies
Vertex (VRTX) PT Raised to $600 at BMO Capital
$600.00
(was $487.57)
Evan David Seigerman
·
BMO Capital
Vertex Pharmaceuticals price target raised to $441 from $411 at Canaccord
$441.00
(was $491.47)
Canaccord Genuity
Vertex Pharmaceuticals price target raised to $607 from $606 at Barclays
$607.00
(was $491.47)
Eliana Merle
·
Barclays
Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright
$591.00
(was $491.47)
Andrew Fein
·
H.C. Wainwright
Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
$570.00
(was $497.42)
Terence Flynn
·
Morgan Stanley
Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
$558.00
(was $493.98)
Louise Chen
·
Scotiabank
Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
$541.00
(was $496.02)
RBC Capital
Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
$577.00
(was $497.21)
Bernstein
Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald
$590.00
(was $495.11)
Cantor Fitzgerald
Vertex Pharmaceuticals price target raised to $466 from $445 at Stifel
$466.00
(was $465.02)
Paul Matteis
·
Stifel Nicolaus
Vertex Pharmaceuticals price target raised to $518 from $478 at H.C. Wainwright
$518.00
(was $465.02)
Andrew Fein
·
H.C. Wainwright